ArticleFrontiers in bioengineering and biotechnology2022
Epigallocatechin-3-gallate selenium nanoparticles for neuroprotection by scavenging reactive oxygen species and reducing inflammation.
Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies.Journal of Zhejiang University. Science. B · 2025Pooled it
- Chitosan Nanoparticles Unlock the Antioxidant Potential of Epigallocatechin Gallate in Pancreatic and Hepatic Cancer Cell Models.ACS omega · 2026Article
- Amelioration of 5-Fluorouracil-Induced Hepatorenal Toxicity by Epigallocatechin Gallate-Functionalized Selenium Nanoparticles: A Multi-Targeted Protective Approach.International journal of molecular sciences · 2026Article
- Selenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications.Bioactive materials · 2026Review
- Natural flavonoids in multiple sclerosis: molecular insights and emerging therapeutic strategies.Frontiers in immunology · 2026Review
- Selenium Nanoparticles as Versatile Delivery Tools.Pharmaceutics · 2025Review
- A Review of the Potential Use of Antioxidants in Spinal Cord Injuries.Antioxidants (Basel, Switzerland) · 2025Review
- Nanotechnology-Based Plant Antioxidants: A Current Literature Review on Bioavailability and Oxidative Stress.Current nutrition reports · 2025Review
- Natural products protect against spinal cord injury by inhibiting ferroptosis: a literature review.Frontiers in pharmacology · 2025Review
- Studying the potential ameliorative effect of biosynthesized selenium nanoparticles using epigallocatechin gallate against depression in rats.Frontiers in pharmacology · 2025Article
- Regulation of dynamic spatiotemporal inflammation by nanomaterials in spinal cord injury.Journal of nanobiotechnology · 2024Review
- Review
- Selenium Nanoparticles in Protecting the Brain from Stroke: Possible Signaling and Metabolic Mechanisms.Nanomaterials (Basel, Switzerland) · 2024Review
- Role of Nanoparticle-Conjugates and Nanotheranostics in Abrogating Oxidative Stress and Ameliorating Neuroinflammation.Antioxidants (Basel, Switzerland) · 2023Review
- Modulating Inflammation-Mediated Diseases via Natural Phenolic Compounds Loaded in Nanocarrier Systems.Pharmaceutics · 2023Review
- The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment of Spinal Cord Injury.Antioxidants (Basel, Switzerland) · 2023Article
- Recent advances in endogenous neural stem/progenitor cell manipulation for spinal cord injury repair.Theranostics · 2023Review
- Ferroptosis is a new therapeutic target for spinal cord injury.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.